New drug targets Gene-Mutated breast cancer in phase 2 trial
NCT ID NCT06840483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breast cancer. The main goal is to see if the drug shrinks tumors, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zelenectide pevedotin (BT8009)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced breast cancer that has a specific genetic marker (NECTIN4 amplification).
- What could go wrong
- This is an early Phase 2 study with only 66 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche
Ancona, 60126, Italy
-
Compass Oncology - Rose Quarter Cancer Center
Portland, Oregon, 97227, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Hospital Beata Maria Ana
Madrid, 28007, Spain
-
Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Istituto Europeo di Oncologia
Milan, 20141, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST
Meldola, Forli/Cesena, 47014, Italy
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Oncopole Claudius Regaud
Toulouse, 31059, France
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC)
Baltimore, Maryland, 21287, United States
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Texas Oncology San Antonio
San Antonio, Texas, 78240, United States
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
UZ Leuven
Leuven, 3000, Belgium
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?